Product Short Description

MariTide (Maridebart Cafraglutide / AMG 133) is a first-in-class bispecific peptide-antibody conjugate (PAC) engineered for advanced metabolic research. By combining a GLP-1 receptor agonist with a GIP receptor antagonist on a human IgG antibody backbone, this long-acting molecule is designed to modulate signaling pathways involved in satiety and lipid metabolism with a prolonged pharmacokinetic profile.

Product Description

Maridebart Cafraglutide, widely recognized in literature as MariTide (or AMG 133), represents a significant evolution in peptide engineering. Unlike standard synthetic peptides that are rapidly cleared by the kidneys, MariTide is a Peptide-Antibody Conjugate (PAC). This structural integration allows the molecule to utilize the body’s natural FcRn (neonatal Fc receptor) recycling pathway, which diverts the compound from cellular degradation and extends its half-life significantly.

Mechanism of Action

MariTide operates through a “dual-pathway” interaction designed to study metabolic homeostasis:

GLP-1 Receptor Activation: The peptide component binds to GLP-1 receptors, triggering signaling pathways associated with appetite regulation and glycemic control.
GIP Receptor Antagonism: The antibody component specifically blocks the GIP receptor. By inhibiting this pathway, research suggests it may target peripheral adipose tissue and influence lipid accumulation.

Research Applications

This compound is intended for in vitro and in vivo experimental models focusing on:

Neuro-endocrine signaling pathways and satiety regulation.
The interplay between GLP-1 agonism and GIPR antagonism.
Pharmacokinetic studies of peptide-antibody conjugates vs. conventional peptides.
Metabolic markers in adipose tissue research.

Chemical and Molecular Analysis

Attribute	Specification
Compound Name	Maridebart Cafraglutide (MariTide / AMG 133)
Classification	Bispecific Peptide-Antibody Conjugate (PAC)
Structure	Human IgG antibody backbone covalently conjugated to two lipidated GLP-1 receptor agonist peptides
Primary Targets	GLP-1 Receptor (Agonist) / GIP Receptor (Antagonist)
Pharmacokinetics	Engages FcRn recycling pathway; terminal half-life of ~21 days
Storage	Must be stored at recommended laboratory temperatures to maintain protein structural integrity

Reference Materials

Once-Monthly and Extended-Interval Incretin-, Amylin-, and THRβ-Targeting Therapies for Type 2 Diabetes and Obesity: Clinical Evidence and Development Pipelines – MDPI
Once-Monthly Zovaglutide (ZT002) in Adults with Overweight or Obesity and Prediabetes: A Phase 2 Subgroup Analysis | Request PDF – ResearchGate
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept – PubMed
Molecular Mechanisms of Islet Amyloid Polypeptide Aggregation: Towards Chemical Strategies to Prevent Amyloid Formation and to Design Non-Aggregating Peptide Therapeutics – MDPI
Once-Monthly and Extended-Interval Incretin-, Amylin-, and THRβ-Targeting Therapies for Type 2 Diabetes and Obesity: Clinical Evidence and Development Pipelines | Sciety

Disclaimer: This product is intended strictly for research and laboratory use only. It is not approved for human consumption, use in any clinical setting, or medical diagnostics. Users must adhere to institutional biosafety and ethical research guidelines.

The products offered by Modern Aminos are intended strictly for laboratory research purposes only and are sold exclusively to qualified professionals, institutions, and entities. These products are not for human consumption, veterinary use, or any other application involving living organisms, including but not limited to diagnostic, therapeutic, or recreational purposes.

By purchasing this product, you confirm that:

You are a qualified professional or entity with the necessary knowledge, training, and facilities to handle chemical reagents safely and appropriately.
You will use this product in full compliance with all applicable local, state, and federal laws and regulations.

Prohibited Uses

This product is not to be used as an active pharmaceutical ingredient (API) in compounding or manufacturing drugs for human or veterinary use.
It is strictly prohibited to use this product for administration to humans or animals under any circumstances.
Modern Aminos does not condone or permit the use of its products for the development, testing, or production of illegal substances.

Regulatory Compliance

Modern Aminos does not claim that this product is approved by the U.S. Food and Drug Administration (FDA) for any purpose. The statements regarding this product have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Liability Statement

The buyer assumes full responsibility for ensuring the safe handling, storage, and use of this product. Modern Aminos is not liable for any damages, direct or indirect, resulting from improper handling, storage, or unauthorized use of this product. Furthermore, Modern Aminos reserves the right to refuse sales to any individual or entity suspected of misusing its products.

If you have questions about the safe and lawful use of this product, consult a qualified professional with expertise in laboratory research. By proceeding with this purchase, you agree to these terms and conditions.

MariTide (Maridebart Cagraflutide)

MariTide (Maridebart Cagraflutide)